CureLab Oncology Establishes Operations in the Gulf Region

BOSTON, Oct. 21, 2020 /PRNewswire/ --A CureLab Oncology, a clinical-stage pre-IPO biotech company, has commenced operations in the GCC region (Saudi Arabia, Kuwait, the UAE, Qatar, Bahrain, and Oman). CureLab's partners in the region will test the efficacy of the company's DNA-based products against cancers and non-cancerous diseases of chronic inflammation.
CureLab Oncology Establishes Operations in the Gulf Region
CureLab intends to receive market approval for commercialization in the GCC region. Local hospitals and universities will be able to both participate in on-going international trials and become the first research centers to initiate new clinical studies a?? potentially preceding trials with medical centers in Europe and the USA. CureLab has appointed Jihad FakhreddineA as director of business development, representing CureLab in the region. Mr. Fakhreddine is a University of California graduate with post-graduate education at Caltech. After 20+ years of successful business development in the USA and Switzerland, he moved to Dubai to lead international healthcare and fundraising projects."There are horrible diseases that are dominant in the GCC region and rarely seen in the West," said Jihad Fakhreddine. "Now, with CureLab's unique mechanism of action, I am hopeful that we can alleviate the pain and suffering of these patients. We will conduct local research to address this local healthcare tragedy while uniting local and American biomedical talent."
See also:
Leave a comment
  • Latest
  • Read
  • Commented
Calendar Content
«    Ноябрь 2020    »